

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

14 May 2020 (14.05.2020)



(10) International Publication Number

WO 2020/096660 A1

(51) International Patent Classification:

A61P 21/00 (2006.01) A61K 35/37 (2015.01)

(21) International Application Number:

PCT/US2019/041279

(22) International Filing Date:

11 July 2019 (11.07.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/756,286 06 November 2018 (06.11.2018) US

(71) Applicant: MYOS RENS TECHNOLOGY, INC.

[US/US]; 45 Horsehill Road, Suite 106, Cedar Knolls, NJ 07927 (US).

(72) Inventors: MANNELLO, Joseph; C/o Myos Rens Tech-

nology, Inc., 45 Horsehill Road, Suite 106, Cedar Knolls, NJ 07927 (US). PADLIYA, Neerav, D.; C/o Myos Rens Technology, Inc., 45 Horsehill Road, Suite 106, Cedar Knolls, NJ 07927 (US). DARIANI, Maghsoud; C/o Myos Rens Technology, Inc., 45 Horsehill Road, Suite 106, Cedar Knolls, NJ 07927 (US).

(74) Agent: TYRRELL, Kathleen, A. et al.; Licata & Tyrrell

P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: METHODS AND COMPOSITIONS FOR IMPROVING SKELETAL MUSCLE PROTEIN FRACTIONAL SYNTHETIC RATE

(57) Abstract: Methods and egg yolk powder containing compositions for improving skeletal muscle protein fractional synthetic rate (FSR) in mammals and inhibiting or reversing sarcopenia are provided.



WO 2020/096660 A1

**METHODS AND COMPOSITIONS FOR IMPROVING SKELETAL MUSCLE PROTEIN
FRACTIONAL SYNTHETIC RATE**

5 This patent application claims the benefit of priority
from U.S. Provisional Application Serial No. 62/756,286 filed
November 6, 2018, the teachings of which are incorporated by
reference in their entirety.

10 **Field**

Embodiments of the present invention are generally
related to methods and compositions for improving skeletal
muscle protein fractional synthetic rate (FSR) in mammals.

15 **Background**

Muscle loss represents one of the most important causes of
functional decline and loss of independence in older adults.
Age-related muscle loss or sarcopenia is commonly observed in
many older adults and is also characterized by a decrease in
20 the rate of muscle protein synthesis. In addition, low muscle
mass is associated with fall-related injuries which can be
devastating to adults over the age of 60 years, particularly if
they result in bone fractures.

Myostatin, first described in 1997, is a protein in the
25 transforming growth factor β superfamily that is produced by
myotubes and can act in an endocrine, autocrine, and
paracrine fashion (McPherron et al. Nature 1997 387(6628):83-
90). Myostatin binds to a transmembrane receptor protein on
myocytes, activin receptor type IIB, to inhibit the Akt-mTOR
30 pathway, upregulate activity of the ubiquitin-proteasome
pathway, and prevent synthesis of satellite cell replication
and translocation (myoblast proliferation). Activation of

these various pathways either inhibits muscle hypertrophy or promotes muscle atrophy. Inhibition of myostatin by various methods has been shown to interrupt these various pathways, reversing or preventing muscle atrophy in various rodent
5 models of disease states, including disuse atrophy (Bogdanovich et al. Nature 2012 420(6914): 418; Holzbaur et al. Neurobiology of disease 2006 23.3: 697-707; Klimek et al. Biochemical and biophysical research communications 2010 391(3):1548-1554; Murphy et al. Journal of applied
10 physiology 2011 110(4):1065-1072). Long-term myostatin inhibition by gene transfer therapy resulted in increased muscle mass in golden retrievers with muscular dystrophy (Bish et al. Human gene therapy 2011 22(12): 1499-1509).

Recommendations for preventing sarcopenia include
15 exercise, in particular resistance training and adequate nutrition inclusive of protein balanced with non-acid producing foods fruits and vegetables. See <https://iofbonehealth.org/treating-sarcopenia> of the world wide web.

Creatine supplements have been indicated to aid in muscle
20 development for older adults that are following a resistance training program (Brose et al. J Gerontol A Biol Sci Med Sci. 2003 58(1):11-9; Chrusch et al. Med Sci Sports Exerc. 2001 33(12):2111-7).

Maintaining appropriate blood levels of vitamin D may
25 also aid in maintaining muscle strength and physical performance (Mithal et al. Osteoporos Int. 2013 May;24(5):1555-66).

While high-dose testosterone increases muscle power and function, but has a number of potentially limiting side effects
30 (Morley, J.E. Calcif Tissue Int. 2016 Apr;98(4):319-33).

Other drugs in clinical development include selective

androgen receptor molecules, ghrelin agonists, myostatin antibodies, activin IIR antagonists, angiotensin converting enzyme inhibitors, beta antagonists, and fast skeletal muscle troponin activators (Morley, J.E. Calcif Tissue Int. 2016 Apr;98(4):319-33).

As sarcopenia is a major predictor of frailty, hip fracture, disability, and mortality in older adults (Morley, J.E. Calcif Tissue Int. 2016 Apr;98(4):319-33), agents which inhibit and/or reverse sarcopenia are needed.

Summary

An aspect of the present invention relates to a method for improving skeletal muscle protein fractional synthetic rate (FSR) in mammals. The method comprises administering to the mammal a composition comprising egg yolk powder.

In one nonlimiting embodiment, the mammal is an older adult.

In one nonlimiting embodiment, the composition administered is FORTETROPIN.

Another aspect of the present invention relates to a method for inhibiting or reversing sarcopenia in a mammal. The method comprises administering to the mammal a composition comprising egg yolk powder.

In one nonlimiting embodiment, the mammal is an older adult.

In one nonlimiting embodiment, the composition administered is FORTETROPIN.

Brief Description of the Figures

FIG. 1 provides a diagram of the design of a study showing the effects of FORTETROPIN on skeletal muscle protein FSR.

FIG. 2 shows results comparing myofibril proteins fractional synthesis in older adults receiving FORTETROPIN versus cheese powder for 21 days.

FIG. 3 shows results comparing cytoplasmic proteins fractional synthesis in older adults receiving FORTETROPIN versus cheese powder for 21 days.

FIG. 4 shows results comparing mitochondrial proteins fractional synthesis in older adults receiving FORTETROPIN versus cheese powder for 21 days.

FIG. 5 shows results comparing membrane proteins fractional synthesis in older adults receiving FORTETROPIN versus cheese powder for 21 days.

DETAILED DESCRIPTION

The headings used herein are for organizational purposes only and are not meant to be used to limit the scope of the description or the claims. As used throughout this application, the word "may" is used in a permissive sense (i.e., meaning having the potential to), rather than the mandatory sense (i.e., meaning must). Similarly, the words "include", "including", and "includes" mean including but not limited to. To facilitate understanding, like reference numerals have been used, where possible, to designate like elements common to the figures.

The present invention provides methods and compositions for improving skeletal muscle protein fractional synthetic rate (FSR) in mammals. The methods comprise administering to the mammal a composition comprising egg yolk powder.

For purposes of the present invention, by the terms "improve", "improving" or "improvement" with respect to

skeletal muscle protein fractional synthetic rate, it is meant an increase in synthesis of skeletal muscle proteins indicative of muscle growth.

Methods and compositions of the present invention are
5 useful in inhibiting and/or reversing sarcopenia in mammals.

Compositions administered in accordance with the present invention comprise egg yolk powder or one or more proteins and/or lipids derived from egg yolk which are effective in growth and development of lean muscle tissue.

10 In one nonlimiting embodiment, the composition administered is FORTETROPIN. FORTETROPIN is a fertilized egg yolk derived product used as a dietary and nutritional supplement (MYOS RENS TECHNOLOGY INC. CORPORATION Cedar Knolls, NJ). FORTETROPIN has been found to have an abundance
15 of pro-angiogenic and host-defense proteins when compared to unfertilized egg yolk. When administered to humans and rats, FORTETROPIN has been shown to reduce serum myostatin levels and demonstrate a change in downstream signaling pathways supportive of muscle hypertrophy and resulting in an increase
20 in lean body mass. FORTETROPIN may be produced via high pressure pasteurization (HPP) and freeze drying of at least a portion of an egg. A method for production of FORTETROPIN is disclosed in U.S. Patent 8,815,320, teachings of which are herein incorporated by reference in their entirety.

25 In one nonlimiting embodiment, FORTETROPIN production is optimized to enhance potency as it relates to muscle disuse atrophy by modifying one or more egg yolk-related parameters such as, but not limited to, incubation time post-lay, fertility status and breed of chicken.

30 In another nonlimiting embodiment, the composition comprises an avian follistatin such as described in U.S.

Published Patent Application No. 2007/0275036, the disclosure of which is incorporated herein by reference in its entirety and/or other proteins and/or lipids found in avian eggs and which are beneficial in growth and development of lean muscle tissue such as, but not limited to, those described in U.S. Provisional Application Serial No. 62/755,601, the disclosure of which is incorporated herein by reference in its entirety.

For purposes of the present invention, when the phrases "egg yolk powder" or "composition comprising egg yolk powder" are used, they are meant to be inclusive, but are not limited to, egg yolk powder, one or more proteins and/or lipids derived from egg yolk which are effective in growth and development of lean muscle tissue, FORTETROPIN and avian follistatin.

By "mammal" or "mammals" it is meant to include, but is not limited to, humans, apes, monkeys, cows, sheep, goats, dogs, cats, mice, rats, and transgenic species thereof.

In one nonlimiting embodiment, the mammal is an older adult. In one nonlimiting embodiment, the older adult is age 60 or greater.

In one nonlimiting embodiment, the composition comprising egg yolk powder is administered orally on a daily basis, one, two or three times a day.

In one nonlimiting embodiment, the composition comprising egg yolk powder is administered in an amount effective to upregulate mTor pathway activity, downregulate ubiquitin proteasome pathway activity, downregulate serum myostatin levels and/or reduce ActRIIB expression, a receptor for myostatin.

In one nonlimiting embodiment, the composition comprising egg yolk powder is FORTETROPIN administered orally on a daily

basis in an amount ranging from about 5 to about 25 grams/day, about 6.6 to about 19.8 grams/day or about 50 to about 300 mg/kg/day, about 80 to about 250 mg/kg/day in humans. In canines, FORTETROPIN is administered orally on a daily basis
5 in an amount ranging from about 200-1000 mg/kg/day, about 300 to about 900 mg/kg/day.

In some embodiments, the composition comprising egg yolk powder is administered at 300 mg/kg daily (one scoop (6600 mg)/22 kg), or the like or a suitable dosage for the weight
10 and characteristics of the mammal. Dosages may be modified for efficacy, for example, may be administered at a higher or lower dosage or administered more than once daily or less than once daily. Mammals may be dosed to the closest $\frac{1}{2}$ scoop, or the like, without underdosing. The composition may be formed
15 in a powder that may be mixed with other food to facilitate ingestion.

However, as will be understood by the skilled artisan upon reading this disclosure, the compositions described herein can be formulated for administration to a subject via
20 any conventional means including, but not limited to, oral, or buccal.

Moreover, the compositions described herein, can be formulated into any suitable dosage form, including but not limited to, aqueous oral dispersions, liquids, gels, syrups, elixirs, slurries, suspensions and the like, for oral
25 ingestion by an individual in need, solid oral dosage forms, controlled release formulations, fast melt formulations, effervescent formulations, lyophilized formulations, tablets, powders, pills, dragees, capsules, delayed release
30 formulations, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, solid

dosage forms, powders, tablets, capsules, pills, delayed release formulations.

Formulations for oral use can be obtained by mixing one or more solid excipient with one or more of the compounds described herein, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include, for example, fillers such as sugars, including glucose, fructose, lactose, sucrose, mannitol, sorbitol, stevia extract, or sucralose; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others such as: polyvinylpyrrolidone (PVP or povidone) or calcium phosphate. If desired, disintegrating agents may be added, such as the cross-linked croscarmellose sodium, polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Formulations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules

made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.

In some embodiments, the solid dosage forms disclosed herein may be in the form of a tablet, (including a suspension tablet, a fast-melt tablet, a bite-disintegration tablet, a rapid-disintegration tablet, an effervescent tablet, or a caplet), a pill, a powder (including a sterile packaged powder, a dispensable powder, or an effervescent powder) a capsule (including both soft or hard capsules, e.g., capsules made from animal-derived gelatin or plant-derived HPMC, or "sprinkle capsules"), solid dispersion, solid solution, pellets, granules. In other embodiments, the pharmaceutical formulation is in the form of a powder. In still other embodiments, the pharmaceutical formulation is in the form of a tablet. Additionally, formulations described herein may be administered as a single capsule or in multiple capsule dosage form. In some embodiments, the formulation is administered in two, or three, or four, capsules or tablets.

Soft gel or soft gelatin capsules may be prepared, for example, without limitation, by dispersing the formulation in an appropriate vehicle (vegetable oils are commonly used) to form a high viscosity mixture. This mixture is then

encapsulated with a gelatin-based film using technology and machinery known to those in the soft gel industry. The industrial units so formed are then dried to constant weight.

5 In some embodiments, the formulations may include other medicinal or pharmaceutical agents, carriers, diluents, dispersing agents, suspending agents, thickening agents, adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, and/or buffers. In
10 addition, the formulations can also contain other therapeutically valuable substances.

 The formulations described herein can include egg yolk powder and one or more pharmaceutically acceptable additives such as a compatible carrier, binder, filling agent,
15 suspending agent, flavoring agent, sweetening agent, disintegrating agent, dispersing agent, surfactant, lubricant, colorant, diluent, solubilizer, moistening agent, plasticizer, stabilizer, penetration enhancer, wetting agent, anti-foaming agent, antioxidant, preservative, or one
20 or more combination(s) thereof. In still other aspects, using standard coating procedures, a film coating is provided around the formulation of the compound described herein. In one embodiment, some or all of the particles of the compound described herein are coated. In another
25 embodiment, some or all of the particles of the compound described herein are microencapsulated. In still another embodiment, the particles of the compound described herein are not microencapsulated and are uncoated.

 In certain embodiments, compositions may also include
30 one or more pH adjusting agents or buffering agents, including acids such as acetic, boric, citric, lactic,

phosphoric and hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane; and buffers such as

5 citrate/dextrose, sodium bicarbonate and ammonium chloride. Such acids, bases and buffers are included in an amount required to maintain pH of the composition in an acceptable range.

In other embodiments, compositions may also include one

10 or more salts in an amount required to bring osmolality of the composition into an acceptable range. Such salts include those having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions;

15 suitable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate.

Formulations including egg yolk powder, as described herein, may be manufactured in a conventional manner,

20 such as, by way of example only, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.

In certain embodiments, compositions provided herein

25 may also include one or more preservatives to inhibit microbial activity. Suitable preservatives include mercury-containing substances such as merfen and thiomersal; stabilized chlorine dioxide; and quaternary ammonium compounds such as benzalkonium chloride,

30 cetyltrimethylammonium bromide and cetylpyridinium chloride.

Formulations described herein may benefit from antioxidants, metal chelating agents, thiol containing compounds and other general stabilizing agents. Examples of such stabilizing agents, include, but are not limited to: (a) about 0.5% to about 2% w/v glycerol, (b) about 0.1% to about 1% w/v methionine, (c) about 0.1% to about 2% w/v monothioglycerol, (d) about 1 mM to about 10 mM EDTA, (e) about 0.01% to about 2% w/v ascorbic acid, (f) 0.003% to about 0.02% w/v polysorbate 80, (g) 0.001% to about 0.05% w/v. polysorbate 20, (h) arginine, (i) heparin, (j) dextran sulfate, (k) cyclodextrins, (l) pentosan polysulfate and other heparinoids, (m) divalent cations such as magnesium and zinc; or (n) combinations thereof.

Binders imparting cohesive qualities may also be used. Examples include, but are not limited to, alginic acid and salts thereof; cellulose derivatives such as carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, ethylcellulose, and microcrystalline cellulose; microcrystalline dextrose; amylose; magnesium aluminum silicate; polysaccharide acids; bentonites; gelatin; polyvinylpyrrolidone/vinyl acetate copolymer; crosspovidone; povidone; starch; pregelatinized starch; tragacanth, dextrin, a sugar, such as sucrose, glucose, dextrose, molasses, mannitol, sorbitol, xylitol, and lactose; a natural or synthetic gum such as acacia, tragacanth, ghatti gum, mucilage of isapol husks, polyvinylpyrrolidone, larch arabogalactan, polyethylene glycol, waxes, sodium alginate, and the like.

In general, binder levels of 20-70% are used in

powder-filled gelatin capsule formulations. Binder usage level in tablet formulations varies whether direct compression, wet granulation, roller compaction, or usage of other excipients such as fillers which itself can act
5 as moderate binder.

Formulators skilled in art can determine the binder level for the formulations, but binder usage level of up to 70% in tablet formulations is common.

Compositions may further comprise carriers of
10 relatively nontoxic chemical compounds or agents that facilitate the incorporation of a compound into cells or tissues. Nonlimiting examples include binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants,
15 wetting agents, diluents, and the like. Suitable carriers for use in solid dosage forms described herein include, but are not limited to, acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerine, magnesium silicate, sodium
20 caseinate, soy lecithin, sodium chloride, tricalcium phosphate, dipotassium phosphate, sodium stearyl lactylate, carrageenan, monoglyceride, diglyceride, pregelatinized starch, hydroxypropylmethylcellulose,
hydroxypropylmethylcellulose acetate stearate, sucrose,
25 microcrystalline cellulose, lactose, mannitol and the like.

Dispersing agents and/or viscosity modulating agents include materials that control the diffusion and homogeneity of a compound through liquid media or a granulation method or blend method. In some embodiments,
30 these agents also facilitate the effectiveness of a coating or eroding matrix. Nonlimiting examples of

diffusion facilitators/ dispersing agents include hydrophilic polymers, electrolytes, a Tween, PEG, polyvinylpyrrolidone, and carbohydrate-based dispersing agents such as hydroxypropyl celluloses (e.g., HPC, HPC-SL, and HPC-L), hydroxypropyl methylcelluloses (e.g., HPMC K100, HPMC K4M, HPMC K15M, and HPMC K100M), carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate stearate (HPMCAS), noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol (PVA), vinyl pyrrolidone/vinyl acetate copolymer (S630), 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol), poloxamers, block copolymers of ethylene oxide and propylene oxide; and poloxamines, tetrafunctional block copolymers derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine, polyvinylpyrrolidone K12, polyvinylpyrrolidone K17, polyvinylpyrrolidone K25, or polyvinylpyrrolidone K30, polyvinylpyrrolidone/vinyl acetate copolymer (S-630), polyethylene glycol, e.g., the polyethylene glycol can have a molecular weight of about 300 to about 6000, or about 3350 to about 4000, or about 7000 to about 5400, sodium carboxymethylcellulose, methylcellulose, polysorbate-80, sodium alginate, gums, such as, e.g., gum tragacanth and gum acacia, guar gum, xanthans, including xanthan gum, sugars, cellulosics, such as, e.g., sodium carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose, polysorbate-80, sodium alginate, polyethoxylated sorbitan

monolaurate, polyethoxylated sorbitan monolaurate, povidone, carbomers, polyvinyl alcohol (PVA), alginates, chitosans and combinations thereof. Plasticizers such as cellulose or triethyl cellulose can also be used as
5 dispersing agents. Dispersing agents that are particularly useful in liposomal dispersions and self-emulsifying dispersions are dimyristoyl phosphatidyl choline, natural phosphatidyl choline from eggs, natural phosphatidyl glycerol from eggs, cholesterol and isopropyl myristate.

10 Combinations of one or more erosion facilitator with one or more diffusion facilitator can also be used in the present compositions.

Compositions of the present invention may further comprise diluents used to dilute the compound of interest
15 prior to delivery. Diluents can also be used to stabilize compounds because they can provide a more stable environment. Salts dissolved in buffered solutions (which also can provide pH control or maintenance) are utilized as diluents in the art, including, but not limited to a
20 phosphate buffered saline solution. In certain embodiments, diluents increase bulk of the composition to facilitate compression or create sufficient bulk for homogenous blend for capsule filling. Such compounds include e.g., lactose, starch, mannitol, sorbitol, dextrose, microcrystalline
25 cellulose; dibasic calcium phosphate, dicalcium phosphate dihydrate; tricalcium phosphate, calcium phosphate; anhydrous lactose, spray-dried lactose; pregelatinized starch, compressible sugar; mannitol, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose
30 acetate stearate, sucrose-based diluents, confectioner's sugar; monobasic calcium sulfate monohydrate, calcium

sulfate dihydrate; calcium lactate trihydrate, dextrates; hydrolyzed cereal solids, amylose; powdered cellulose, calcium carbonate; glycine, kaolin; sodium chloride; inositol, bentonite, and the like.

5 Compositions may further comprise an enteric coating, a substance that remains substantially intact in the stomach but dissolves and releases the egg yolk powder in the small intestine or colon. Generally, the enteric coating comprises a polymeric material that prevents release in the low pH
10 environment of the stomach but that ionizes at a higher pH, typically a pH of 6 to 7, and thus dissolves sufficiently in the small intestine or colon to release the active agent therein.

 In addition, the compositions may comprise an erosion
15 facilitator, a material that controls the erosion of a particular material in gastrointestinal fluid. Erosion facilitators are generally known to those of ordinary skill in the art. Exemplary erosion facilitators include, e.g., hydrophilic polymers, electrolytes, proteins, peptides, and
20 amino acids.

 Filling agents including compounds such as lactose, calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium sulfate, microcrystalline cellulose, cellulose powder, dextrose, dextrates, dextran, starches,
25 pregelatinized starch, sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol, and the like can also be included in the compositions. Suitable filling agents for use in the solid dosage forms described herein include, but are not limited to, lactose, calcium carbonate,
30 calcium phosphate, dibasic calcium phosphate, calcium sulfate, microcrystalline cellulose, cellulose powder,

dextrose, dextrates, dextran, starches, pregelatinized starch, hydroxypropylmethycellulose (HPMC), hydroxypropylmethycellulose phthalate, hydroxypropylmethylcellulose acetate stearate (HPMCAS),
5 sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol, and the like.

In addition, flavoring agents and/or sweeteners can be used in the compositions and may include acacia syrup, acesulfame K, alitame, anise, apple, aspartame, banana,
10 Bavarian cream, berry, black currant, butterscotch, calcium citrate, camphor, caramel, cherry, cherry cream, chocolate, cinnamon, bubble gum, citrus, citrus punch, citrus cream, cotton candy, cocoa, cola, cool cherry, cool citrus, cyclamate, cylamate, dextrose, eucalyptus, eugenol,
15 fructose, fruit punch, ginger, glycyrrhetinate, glycyrrhiza (licorice) syrup, grape, grapefruit, honey, isomalt, lemon, lime, lemon cream, monoammonium glycyrrhizinate, maltol, mannitol, maple, marshmallow, menthol, mint cream, mixed berry, neohesperidine DC, neotame, orange, pear, peach,
20 peppermint, peppermint cream, raspberry, root beer, rum, saccharin, safrole, sorbitol, spearmint, spearmint cream, strawberry, strawberry cream, stevia, sucralose, sucrose, sodium saccharin, saccharin, aspartame, acesulfame potassium, mannitol, talin, xylitol, sucralose, sorbitol,
25 Swiss cream, tagatose, tangerine, thaumatin, tutti frutti, vanilla, walnut, watermelon, wild cherry, wintergreen, xylitol, or any combination of these flavoring ingredients, e.g., anise-menthol, cherry- anise, cinnamon-orange, cherry-cinnamon, chocolate-mint, honey-lemon, lemon-lime, lemon-
30 mint, menthol-eucalyptus, orange-cream, vanilla-mint, and mixtures thereof.

The compositions may further comprise lubricants and/or glidants that prevent, reduce or inhibit adhesion or friction of materials. Nonlimiting examples of lubricants include stearic acid, calcium hydroxide, talc, sodium stearyl fumarate, a hydrocarbon such as mineral oil, or hydrogenated vegetable oil such as hydrogenated soybean oil, higher fatty acids and their alkali-metal and alkaline earth metal salts, such as aluminum, calcium, magnesium, zinc, stearic acid, sodium stearates, glycerol, talc, waxes, boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine, a polyethylene glycol (e.g., PEG-4000) or a methoxypolyethylene glycol, sodium oleate, sodium benzoate, glyceryl behenate, polyethylene glycol, magnesium or sodium lauryl sulfate, colloidal silica, a starch such as corn starch, silicone oil, a surfactant, and the like.

Plasticizers, compounds used to soften the microencapsulation material or film coatings to make them less brittle may also be included in the compositions. Examples of suitable plasticizers include, but are not limited to, polyethylene glycols such as PEG 300, PEG 400, PEG 600, PEG 1450, PEG 3350, and PEG 800, stearic acid, propylene glycol, oleic acid, triethyl cellulose and triacetin. In some embodiments, plasticizers can also function as dispersing agents or wetting agents.

The compositions may further comprise solubilizers such as triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, sodium lauryl sulfate, sodium doccusate, vitamin E TPGS, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropylmethyl cellulose, hydroxypropyl cyclodextrins, ethanol, n-butanol, isopropyl alcohol,

cholesterol, bile salts, polyethylene glycol 200-600, glycofurool, transcutool, propylene glycol, and dimethyl isosorbide and the like.

In addition, the compositions may comprise
5 stabilizers such as antioxidation agents, buffers, acids, preservatives and the like.

Suitable suspending agents for use in solid dosage forms described here include, but are not limited to, polyvinylpyrrolidone, e.g., polyvinylpyrrolidone K12,
10 polyvinylpyrrolidone K17, polyvinylpyrrolidone K25, or polyvinylpyrrolidone K30, polyethylene glycol, e.g., the polyethylene glycol can have a molecular weight of about 300 to about 6000, or about 3350 to about 4000, or about 7000 to about 5400, vinyl pyrrolidone/vinyl acetate
15 copolymer (S630), sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, polysorbate-80, hydroxyethylcellulose, sodium alginate, gums, such as, e.g., gum tragacanth and gum acacia, guar gum, xanthans, including xanthan gum, sugars,
20 cellulosics, such as, e.g., sodium carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, polysorbate-80, sodium alginate, polyethoxylated sorbitan monolaurate, polyethoxylated
25 sorbitan monolaurate, povidone and the like.

Surfactants including compounds such as sodium lauryl sulfate, sodium docusate, Tweens, triacetin, vitamin E TPGS, sorbitan monooleate, polyoxyethylene sorbitan monooleate, polysorbates, polaxomers, bile salts,
30 glyceryl monostearate, copolymers of ethylene oxide and propylene oxide and the like may also be included.

Additional surfactants include polyoxyethylene fatty acid glycerides and vegetable oils, e.g., polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylene alkylethers and alkylphenyl ethers, e.g., octoxynol 10, octoxynol 40.

5 In some embodiments, surfactants may be included to enhance physical stability or for other purposes.

Viscosity enhancing agents including, e.g., methyl cellulose, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose,
10 hydroxypropylmethyl cellulose acetate stearate, hydroxypropylmethyl cellulose phthalate, carbomer, polyvinyl alcohol, alginates, acacia, chitosans and combinations thereof may also be included.

In addition, wetting agents including compounds such as
15 oleic acid, glyceryl monostearate, sorbitan monooleate, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, sodium docusate, sodium oleate, sodium lauryl sulfate, sodium doccusate, triacetin, Tween 80,
20 vitamin E TPGS, ammonium salts and the like may be included in these compositions.

In some embodiments, solid dosage forms, e.g., tablets, capsules, are prepared by mixing the egg yolk powder described herein, with one or more pharmaceutical excipients
25 to form a bulk blend composition. When referring to these bulk blend compositions as homogeneous, it is meant that the particles of egg yolk powder, are dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms,
30 such as tablets, pills, and capsules.

Conventional techniques include, e.g., one or a

combination of methods: (1) dry mixing, (2) direct
compression, (3) milling, (4) dry or non-aqueous
granulation, (5) wet granulation, or (6) fusion. See, e.g.,
Lachman *et al.*, "The Theory and Practice of Industrial
5 Pharmacy" (1986).

It should be appreciated that there is considerable
overlap between additives used in the solid dosage forms
described herein. Thus, the above-listed additives should
be taken as merely exemplary, and not limiting, of the
10 types of additives that can be included.

A capsule may be prepared, for example, by placing
the bulk blend of the formulation of the compound
described above, inside of a capsule. In some embodiments,
the formulations (non-aqueous suspensions and solutions)
15 are placed in a soft gelatin capsule. In other
embodiments, the formulations are placed in standard
gelatin capsules or non-gelatin capsules such as capsules
comprising HPMC. In other embodiments, the formulation is
placed in a sprinkle capsule, wherein the capsule may be
20 swallowed whole or the capsule may be opened and the
contents sprinkled on food prior to eating. In some
embodiments, the therapeutic dose is split into multiple
(e.g., two, three, or four) capsules. In some
embodiments, the entire dose of the formulation is
25 delivered in a capsule form.

In another aspect, dosage forms may include
microencapsulated formulations. In some embodiments, one or
more other compatible materials are present in the
microencapsulation material. Exemplary materials include,
30 but are not limited to, pH modifiers, erosion facilitators,
anti-foaming agents, antioxidants, flavoring agents, and

carrier materials such as binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, and diluents.

5 Materials useful for the microencapsulation described herein include materials which sufficiently isolate the compound from other non-compatible excipients. Materials compatible with the egg yolk powder are those that delay the release of the egg yolk powder *in vivo*.

10 In other embodiments, the formulations described herein, which include the egg yolk powder, are solid dispersions. Methods of producing such solid dispersions are known in the art and include, but are not limited to, for example, U.S. Pat. Nos. 4,343,789, 5,340,591, 5,456,923,
15 5,700,485, 5,723,269, and U.S. Pub. Appl 2004/0013734.

 In still other embodiments, the formulations described herein are solid solutions. Solid solutions incorporate a substance together with the active agent and other excipients such that heating the mixture results in
20 dissolution of the drug and the resulting composition is then cooled to provide a solid blend which can be further formulated or directly added to a capsule or compressed into a tablet. Methods of producing such solid solutions are known in the art and include, but are not limited to, for
25 example, U.S. Pat. Nos. 4,151,273, 5,281,420, and 6,083,518.

 In some embodiments, the solid dosage forms described herein can be formulated as enteric coated delayed release oral dosage forms, i.e., as an oral dosage form of a pharmaceutical composition as described herein which
30 utilizes an enteric coating to affect release in the small intestine of the gastrointestinal tract. The enteric coated

dosage form may be a compressed or molded or extruded tablet/mold (coated or uncoated) containing granules, powder, pellets, beads or particles of the active ingredient and/or other composition components. The enteric coated oral
5 dosage form may also be a capsule (coated or uncoated) containing pellets, beads or granules of the solid carrier or the composition.

The term "delayed release" as used herein refers to the delivery so that the release can be accomplished at some
10 generally predictable location in the intestinal tract more distal to that which would have been accomplished if there had been no delayed release alterations. In some embodiments the method for delay of release is coating. Any coatings should be applied to a sufficient thickness such that the
15 entire coating does not dissolve in the gastrointestinal fluids at pH below about 5, but does dissolve at pH about 5 and above. It is expected that any anionic polymer exhibiting a pH-dependent solubility profile can be used as an enteric coating for the methods and compositions
20 described herein to achieve delivery to the lower gastrointestinal tract.

In some embodiments, formulations are provided that include particles of egg yolk powder described herein and at least one dispersing agent or suspending agent for oral
25 administration to a subject. The formulations may be a powder and/or granules for suspension, and upon admixture with water, a substantially uniform suspension is obtained.

Liquid formulation dosage forms for oral administration can be aqueous suspensions selected from the group
30 including, but not limited to, pharmaceutically acceptable aqueous oral dispersions, emulsions, solutions, elixirs,

gels, and syrups. See, e.g., Singh et al., Encyclopedia of Pharmaceutical Technology, 2nd Ed., pp. 754-757 (2002). In addition to the particles of egg yolk powder, the liquid dosage forms may include additives, such as: (a)

5 disintegrating agents; (b) dispersing agents; (c) wetting agents; (d) at least one preservative, (e) viscosity enhancing agents, (t) at least one sweetening agent, and (g) at least one flavoring agent. In some embodiments, the aqueous dispersions can further include a crystalline
10 inhibitor.

The aqueous suspensions and dispersions described herein can remain in a homogenous state, as defined in The USP Pharmacists' Pharmacopeia (2005 edition, chapter 905), for at least 4 hours. The homogeneity should be determined
15 by a sampling method consistent with regards to determining homogeneity of the entire composition. In one embodiment, an aqueous suspension can be re-suspended into a homogenous suspension by physical agitation lasting less than 1 minute. In another embodiment, an aqueous suspension can be re-
20 suspended into a homogenous suspension by physical agitation lasting less than 45 seconds. In yet another embodiment, an aqueous suspension can be re-suspended into a homogenous suspension by physical agitation lasting less than 30 seconds. In still another embodiment, no agitation is
25 necessary to maintain a homogeneous aqueous dispersion.

Suitable preservatives for the aqueous suspensions or dispersions described herein include, for example, potassium sorbate, parabens (e.g., methylparaben and propylparaben), benzoic acid and its salts, other esters of
30 parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl alcohol or benzyl alcohol, phenolic compounds such

as phenol, or quaternary compounds such as benzalkonium chloride. Preservatives, as used herein, are incorporated into the dosage form at a concentration sufficient to inhibit microbial growth.

5 In one nonlimiting embodiment, the aqueous liquid dispersion can comprise a sweetening agent or flavoring agent in a concentration ranging from about 0.005% to about 0.5% the volume of the aqueous dispersion. In yet another embodiment, the aqueous liquid dispersion can comprise a
10 sweetening agent or flavoring agent in a concentration ranging from about 0.01% to about 1.0% the volume of the aqueous dispersion.

 In addition to the additives listed above, the liquid formulations can also include inert diluents commonly used
15 in the art, such as water or other solvents, solubilizing agents, and emulsifiers. Exemplary emulsifiers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, sodium lauryl sulfate,
20 sodium doccusate, cholesterol, cholesterol esters, taurocholic acid, phosphatidylcholine, oils, such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols, fatty acid esters of
25 sorbitan, or mixtures of these substances, and the like.

 In some embodiments, the formulations described herein can be self-emulsifying drug delivery systems (SEDDS). Emulsions are dispersions of one immiscible phase in another, usually in the form of droplets. Generally,
30 emulsions are created by vigorous mechanical dispersion.

 SEDDS, as opposed to emulsions or microemulsions,

spontaneously form emulsions when added to an excess of water without any external mechanical dispersion or agitation. An advantage of SEDDS is that only gentle mixing is required to distribute the droplets throughout the solution. Additionally, water or the aqueous phase can be added just prior to administration, which ensures stability of an unstable or hydrophobic active ingredient. Thus, the SEDDS provides an effective delivery system for oral and parenteral delivery of hydrophobic active ingredients. SEDDS may provide improvements in the bioavailability of hydrophobic active ingredients. Methods of producing self-emulsifying dosage forms are known in the art and include, but are not limited to, for example, U.S. Pat. Nos. 5,858,401, 6,667,048, and 6,960,563.

Buccal formulations that include egg yolk powder may be administered using a variety of formulations known in the art. For example, such formulations include, but are not limited to, U.S. Pat. Nos. 4,229,447, 4,596,795, 4,755,386, and 5,739,136. In addition, the buccal dosage forms described herein can further include a bioerodible (hydrolysable) polymeric carrier that also serves to adhere the dosage form to the buccal mucosa. The buccal dosage form is fabricated so as to erode gradually over a predetermined time period. Buccal drug delivery, as will be appreciated by those skilled in the art, avoids the disadvantages encountered with oral drug administration, e.g., slow absorption, degradation of the active agent by fluids present in the gastrointestinal tract and/or first-pass inactivation in the liver. With regard to the bioerodible (hydrolysable) polymeric carrier, it will be appreciated that virtually any such carrier can be used,

so long as the desired drug release profile is not compromised, and the carrier is compatible with the egg yolk powder, and any other components that may be present in the buccal dosage unit. Generally, the polymeric
5 carrier comprises hydrophilic (water-soluble and water-swella-ble) polymers that adhere to the wet surface of the buccal mucosa. Other components may also be incorporated into the buccal dosage forms described herein include, but are not limited to, disintegrants,
10 diluents, binders, lubricants, flavoring, colorants, preservatives, and the like. For buccal or sublingual administration, the compositions may take the form of tablets, lozenges, or gels formulated in a conventional manner.

15 In certain embodiments, delivery systems for pharmaceutical compounds may be employed, such as, for example, liposomes and emulsions. In certain embodiments, compositions provided herein can also include a mucoadhesive polymer, selected from among, for example,
20 carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methylmethacrylate), polyacrylamide, polycarbophil, acrylic acid/butyl acrylate copolymer, sodium alginate and dextran.

The invention is further illustrated by the following
25 example, which should not be construed as further limiting. The contents of all references, pending patent applications, and published patents cited throughout this application are hereby expressly incorporated by reference.

EXAMPLE

30 One benefit of embodiments of the present invention is the effect of egg yolk powder supplementation on the

FSR of muscle proteins in men and women between 60 and 75 years old, or of different ages, or the like. In 10 men (n=6) and women (n=4) between 60 and 75 years old, with a BMI between 23 and 29, ingestion of FORTETROPIN (compared with placebo) for 21 days resulted in an increase in the fractional synthetic rate of skeletal muscle proteins as compared to 10 men (n=4) and women (n=6) treated with cheese powder. Design of this FSR study is depicted in FIG. 1. As shown in FIGs. 2 through 4, the average fractional synthesis of a majority of skeletal muscle proteins in several gene ontologies was statistically significantly higher in the FORTETROPIN group (33/38 myofibril proteins (see FIG. 2), 36/44 cytoplasmic proteins (See FIG. 3) and 15/19 mitochondrial proteins (see FIG. 4)). The overall magnitude of increase was 15% indicating a stimulatory effect of the egg yolk powder composition on muscle protein synthesis. Further, these effects were independent of gender or base line muscle mass of the subjects.

Subjects: The study was comprised of 10 control subjects of 4 men and 6 women and 10 FORTETROPIN subjects of 6 men and 4 women with an average age of 66.35 ± 4.45 years.

Dosing with $^2\text{H}_2\text{O}$: All subjects in this study consumed approximately 100-150 ml of 70% $^2\text{H}_2\text{O}$, divided into two to three 50 ml doses for 21 consecutive days. On the first day of dosing, subjects remained at a clinical site for the initial bolus doses. During the initial four days, each subject drank 150 ml of $^2\text{H}_2\text{O}$ divided into 50 ml doses consumed at least 3 hours apart, at approximately 9:00 AM, 1:00PM, and

5:00 PM. This is a bolus dose to increase body water enrichment with $^2\text{H}_2\text{O}$ rapidly to isotopic steady state (between 1.5% and 2% enrichment). The subjects then continued to consume 100ml of 70% $^2\text{H}_2\text{O}$ divided into 2 doses each day of 50ml (morning and evening) for the remaining 17 days of methods to remain at steady state.

D3-creatine dilution for muscle mass: A 30 mg capsule of D3-creatine was swallowed by each subject three days prior to initiation of FORTETROPIN treatment and the first day of $^2\text{H}_2\text{O}$ dosing. Subjects did not need to be in the fasted condition for this dose. Three days after the dose of D3-creatine, a morning fasted urine sample was collected. Subjects were told to void upon waking and the second void was collected. No food was consumed until the second urine void was collected. The urine sample was frozen as soon as possible. Muscle mass, and in particular an increase in muscle mass, was used as a variable in examination of the response to FORTETROPIN.

Saliva: Saliva samples were collected to measure $^2\text{H}_2\text{O}$ enrichment on days 4, 7, 14 and 21. The enrichment of body water was used to calculate muscle protein FSR.

Muscle biopsy: After 21 days of treatment with FORTETROPIN, a micro muscle biopsy was collected on each subject midway between the patella and greater trochanter from the *vastus lateralis*. About 15 mg of tissue was obtained. Muscle sample were removed from the needle, placed in a plastic storage vial and frozen rapidly in liquid nitrogen. Samples were stored in a -70°C freezer in accordance with exemplary embodiments.

Treatment: Subjects were provided and asked to consume three packets of FORTETROPIN powder or placebo (isocaloric amount of cheddar cheese, 1.5 oz) at 9:00 PM each evening, or the like.

5 **Blood samples:** Two blood samples were collected from each subject; one at baseline (study day -3) and one exactly 12 hours after the final dose of FORTETROPIN or placebo was consumed. Blood samples were frozen immediately and stored in a -40°C freezer for later analysis of circulating myostatin
10 levels. Height was measured on each subject and body weight was measured weekly.

Statistical Power: Twenty (20) evaluable subject (10 in the FORTETROPIN arm and 10 in the placebo arm) were required to
15 provide 80% power with a two-sided alpha of 0.05 to demonstrate the superiority of FORTETROPIN versus placebo with respect to the primary endpoint (muscle protein fractional synthesis rate). This estimate assumes a within group standard deviation (SD) of 0.25% /hr, with no change in FSR in the
20 placebo group, and a 0.30% /hr increase with FORTETROPIN treatment.

While the foregoing is directed to embodiments of the present invention, other and further embodiments of the
25 invention may be devised without departing from the basic scope thereof. For example, although numerous embodiments having various features have been described herein, combinations of such various features in other combinations not discussed herein are contemplated within the scope of
30 embodiments of the present invention.

What is Claimed is:

1. A method for improving skeletal muscle protein fractional synthetic rate (FSR) in mammals, said method comprising administering to the mammal a composition comprising egg yolk powder.

2. The method of claim 1 wherein the mammal is an older adult.

3. The method of claim 1 or 2 wherein the composition comprises a fertilized egg yolk derived product.

4. The method of claim 3 wherein the fertilized egg yolk derived product is FORTETROPIN.

5. The method of any of the preceding claims wherein the egg yolk powder is administered in an amount effective to upregulate mTor pathway activity, downregulate ubiquitin proteasome pathway activity, downregulate serum myostatin levels and/or reduce ActRIIB expression.

6. The method of claim 1 or 2 wherein the composition comprises avian follistatin.

7. A method for inhibiting or reversing sarcopenia in a mammal, said method comprising administering to the mammal a composition comprising egg yolk powder.

8. The method of claim 7 wherein the mammal is an older adult.

9. The method of claim 7 or 8 wherein the composition comprises a fertilized egg yolk derived product.

10. The method of claim 9 wherein the fertilized egg yolk derived product is FORTETROPIN.

5 11. The method of any of claims 7, 8, 9 or 10 wherein the egg yolk powder is administered in an amount effective to upregulate mTor pathway activity, downregulate ubiquitin proteasome pathway activity, downregulate serum myostatin levels and/or reduce ActRIIB expression.

10

12. The method of claim 7 or 8 wherein the composition comprises avian follistatin.

Effects of Fortetropin on skeletal muscle protein FSR
Study Design




FIG. 1

Myofibril Proteins Fractional Synthesis Increased for 33/38 proteins in Fortetropin group compared to Control
Mean Magnitude of Increase = 14%
p < 0.0001 for proportion of increased proteins, 2-tailed Binomial Test




FIG. 2

Cytoplasmic Proteins Fractional Synthesis Increased for 36/44 proteins in Fortetropin Group compared to Control
Mean Magnitude of Increase = 13%
p < 0.0001 for proportion of increased proteins, 2-tailed Binomial Test




FIG. 3

Mitochondrial Proteins Fractional Synthesis Increased for 15/19 proteins in Fortetropin Group compared to Control
Mean Magnitude of Increase = 18%
p < 0.0001 for proportion of increased proteins, 2-tailed Binomial Test




FIG. 4

Fractional Synthesis Increased for 1 ECM, 4/5 ER, 1/2 Membrane proteins in Fortetropin Group compared to Control
Not significant for proportion of increased proteins, Binomial Test




FIG. 5

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2019/041279

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61P21/00 A61K35/57
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61P A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	US 2007/275036 A1 (GREEN III RICHARD P [US] ET AL) 29 November 2007 (2007-11-29) paragraphs [0010], [0044], [0054], [0057]; claims 1-3,7 ----- -/--	1-9,11, 12 10



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

7 October 2019

Date of mailing of the international search report

14/10/2019

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Rodrigo-Simón, Ana

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2019/041279

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SHARP MH ET AL: "The Effects of Fortetropin Supplementation on Body Composition, Strength, and Power in Humans and Mechanism of Action in a Rodent Model", JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, AMERICAN COLLEGE OF NUTRITION, WILMINGTON, NC, US , vol. 35, no. 8 1 November 2016 (2016-11-01), pages 679-691, XP009516325, ISSN: 0731-5724, DOI: 10.1080/07315724.2016.1142403 Retrieved from the Internet: URL:http://www.ncbi.nlm.nih.gov/pubmed/27333407 [retrieved on 2016-06-22] the whole document	10
A	WILSON JACOB ET AL: "The Effects of Fertilized Egg Yolk Isolates on Anabolic and Catabolic Signaling in Skeletal Muscle", THE FASEB JOURNAL; EXPERIMENTAL BIOLOGY MEETING 2015; BOSTON, MA, USA; MARCH 28 -APRIL 01, 2015, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, US, vol. 29, no. Suppl. 1, 31 March 2015 (2015-03-31), page 819.1, XP009516326, ISSN: 0892-6638 abstract	10
A	WO 2008/067480 A2 (NATIONWIDE CHILDRENS HOSPITAL [US]; KASPAR BRIAN K [US] ET AL.) 5 June 2008 (2008-06-05) claim 26	10
A	SRINIVASAN DASARATHY ET AL: "Sarcopenia associated with portosystemic shunting is reversed by follistatin", JOURNAL OF HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 54, no. 5, 7 August 2010 (2010-08-07), pages 915-921, XP028192150, ISSN: 0168-8278, DOI: 10.1016/J.JHEP.2010.08.032 [retrieved on 2010-10-24] the whole document	10
A	EP 2 674 033 A1 (DEUTSCHES INST LEBENSMITTELTEC [DE]) 18 December 2013 (2013-12-18) claims 1-10	10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2019/041279

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2007275036 A1	29-11-2007	US 2007275036 A1	29-11-2007
		US 2018021388 A1	25-01-2018

WO 2008067480 A2	05-06-2008	CA 2693178 A1	05-06-2008
		EP 2097095 A2	09-09-2009
		EP 2679237 A1	01-01-2014
		ES 2569365 T3	10-05-2016
		US 2010178348 A1	15-07-2010
		US 2015086636 A1	26-03-2015
		US 2017151348 A1	01-06-2017
		WO 2008067480 A2	05-06-2008

EP 2674033 A1	18-12-2013	BR 112014031051 A2	27-06-2017
		EP 2674033 A1	18-12-2013
		EP 2806745 A1	03-12-2014
		ES 2561381 T3	25-02-2016
		US 2013330455 A1	12-12-2013
		US 2015141334 A1	21-05-2015
		US 2017215442 A1	03-08-2017
		US 2018368425 A1	27-12-2018
		WO 2013186234 A1	19-12-2013
